Add us on Google

PSA Screening Guidelines: Who Should Get a PSA Test, and Why Fewer Low-Risk Cancers Are Treated

What the AUA and USPSTF say about PSA screening by age and risk, and how a shift to active surveillance changes the overtreatment concern.

Published

October 26, 2026

Read time

9 min read

Medically reviewed by

Rhonda Collins, FNP-C

Share

Copy link

Summarize with AI

Current PSA screening guidelines treat the test as a decision that depends on age, risk, and how a man weighs the trade-offs, not as a test for everyone. The American Urological Association (AUA) and Society of Urologic Oncology (SUO) guideline, amended February 26, 2026, says clinicians may offer a baseline PSA test between ages 45 and 50 at average risk, should offer screening from 40 to 45 at increased risk, and should offer regular screening every 2 to 4 years from 50 to 69. ^[1] The U.S. Preventive Services Task Force (USPSTF) frames screening as an individual decision from 55 to 69 and recommends against it at 70 and older. ^[2]

For years, overtreatment of cancers that would never have caused harm was the main argument against PSA screening. ^[2] A University of Michigan analysis published October 26, 2026, in Cancer shows most men diagnosed with low-risk prostate cancer in the U.S. no longer have surgery or radiation. The share avoiding both rose from about a third in 2010 to 83% in 2023 in national cancer registry data, and to 96% in the VA by 2024. The researchers describe this as a nationwide shift toward active surveillance. ^[3]

This guide covers the screening ages and intervals in current guidelines, why overtreatment shaped them, what the 2026 study found, what active surveillance involves, and what one PSA result can tell you.

PSA screening guidelines by age and risk

The AUA/SUO Early Detection of Prostate Cancer guideline, amended February 26, 2026, says clinicians may offer a baseline PSA test between ages 45 and 50 for people at average risk. It is a conditional recommendation. ^[1]

The guideline’s screening ages and intervals: ^[1]

The guideline calls for shared decision-making before screening, and for PSA to be the first screening test. ^[1]

The AUA/SUO and USPSTF guidance differ on when the conversation starts. The AUA/SUO guideline offers a baseline test from 45 to 50, or 40 to 45 at higher risk. The USPSTF frames screening as an individual decision from 55 to 69. ^[1][2] Neither recommends screening for everyone. Both treat it as a decision that depends on age, risk, and how a man weighs the trade-offs.

For a man in those age ranges who wants a starting point, a single baseline PSA is the practical first step. Mito lists a total PSA test with reflex to free PSA, which measures total PSA and adds free PSA when the total result calls for it.

How often PSA screening is recommended

For people aged 50 to 69, the AUA/SUO guideline says clinicians should offer regular PSA screening every 2 to 4 years. It is a strong recommendation. ^[1]

The guideline lets clinicians personalize the re-screening interval, or stop screening, based on preference, age, PSA, risk, life expectancy, and general health. It notes the interval can be longer for people aged 45 to 70 whose PSA is below 1 ng/mL or below the median for their age. ^[1]

Why overtreatment shaped PSA screening guidelines

The USPSTF calls overdiagnosis one of the most important harms of PSA screening, and that harm is the reason its guidance is cautious. Its current final recommendation, from 2018, says the decision to have periodic PSA screening at ages 55 to 69 should be an individual one (grade C). It recommends against PSA screening at 70 and older (grade D). ^[2]

Overdiagnosis means finding a cancer that would never have caused symptoms in a man’s lifetime. The Task Force cites trial follow-up suggesting that 20% to 50% of men diagnosed through screening may be overdiagnosed. When those men are treated, they carry the side effects without any benefit. ^[2]

The Task Force summarized those side effects this way: ^[2]

• About 1 in 5 men who have a radical prostatectomy develop long-term urinary incontinence that requires pads, and 2 in 3 experience long-term erectile dysfunction.
• More than half of men who receive radiation therapy experience long-term erectile dysfunction, and up to 1 in 6 have long-term bothersome bowel symptoms.

The Task Force concluded with moderate certainty that the net benefit of PSA screening for men aged 55 to 69 is small for some men, and that how each man weighs the specific benefits and harms decides whether it is worthwhile. Its prostate cancer screening topic is marked as being updated, but as of October 2026 the 2018 statement remains its current final recommendation. ^[2]

How often low-risk prostate cancer is treated now

Among men diagnosed with low-risk prostate cancer, the share who received neither radiation nor surgery to remove the prostate (radical prostatectomy) rose from 33.6% to 83.4% in the national SEER cancer registry between 2010 and 2023. In the Veterans Affairs (VA) health system, it rose from 51.6% to 96.3% between 2010 and 2024. ^[3]

The study, by Monda and colleagues at the University of Michigan and the VA Ann Arbor Healthcare System, defined low-risk prostate cancer as Grade Group 1 disease, a PSA below 10 ng/mL, and clinical stage T2a or lower. It reported three trends: ^[3]

The radiation analysis covered 207,196 patients treated with radiation for localized prostate cancer across SEER, the VA, and the Michigan Radiation Oncology Quality Consortium (MROQC). In MROQC, which covered 2021 to 2025, low-risk disease stayed at 4.2% or less of radiation-treated patients. The declines persisted after statistical adjustment. ^[3]

Two limits matter. First, “neither radiation nor prostatectomy” is a proxy. It does not measure how many men were actually enrolled in a structured active surveillance program, so the study does not show that 83% of low-risk men are on active surveillance specifically. Second, the study describes treatment patterns. It did not test whether PSA screening lowers prostate cancer deaths. ^[3]

The study speaks to the harm side of the USPSTF’s weighing. If a man diagnosed with low-risk cancer today is far less likely to be treated, the treatment side effects listed in the USPSTF statement apply to fewer screen-detected men than they did when the guidance was written. The study does not change the evidence on the benefit side. ^[2][3]

What active surveillance for prostate cancer involves

Active surveillance means monitoring a low-risk prostate cancer with regular tests and treating it only if it shows signs of becoming more aggressive. The American Urological Association (AUA) and American Society for Radiation Oncology (ASTRO) guideline recommends active surveillance as the preferred option for low-risk prostate cancer, a strong recommendation. ^[4]

The same guideline describes the core of a surveillance plan: ^[4]

• Serial PSA tests, in general no more often than every six months.
• A symptom check and physical exam with a digital rectal exam (DRE) every one to two years.
• Repeat prostate biopsy at intervals.
• Prostate MRI to refine risk. The guideline says MRI should not replace periodic surveillance biopsy.

The schedule can be individualized. Men at low risk of progression or with a more limited life expectancy may follow a less intensive plan. ^[4]

A rising PSA during surveillance first prompts a repeat PSA test, because temporary rises are common. Repeated PSA increases, a new finding on DRE, or other signs of progression prompt an MRI and possibly a biopsy. Finding a significantly larger or higher-grade cancer on a surveillance biopsy prompts a discussion of treatment, weighed against age, other health conditions, life expectancy, and personal preference. ^[4]

Active surveillance is different from watchful waiting. Watchful waiting, which the guideline recommends for men with limited life expectancy and no symptoms, does not include ongoing cancer testing such as biopsy. ^[4] The guideline also notes that cohort studies of men on active surveillance for low-risk disease have consistently shown low rates of metastasis (under 1.5%) and prostate cancer death (under 1%) within 10 years of diagnosis. ^[4]

What one PSA result can and cannot tell you

One PSA result is a starting point, not a diagnosis. There is no single threshold that separates a normal from an abnormal PSA, and benign conditions such as an enlarged prostate (benign prostatic hyperplasia) and prostatitis can raise it. Recent ejaculation, vigorous cycling, and a recent prostate biopsy can raise it temporarily. ^[5]

For a newly elevated PSA, the AUA/SUO guideline says clinicians should repeat the PSA before moving to another biomarker, imaging, or biopsy. ^[1] The guideline also supports validated risk calculators to inform a biopsy decision. Those tools can draw on age, total PSA, PSA density, and percent free PSA. ^[1]

For published age-banded reference values, and the factors that can push a result up or down, see normal PSA levels by age. If a total result needs more context, the free and total PSA test reports total PSA, free PSA, and the percent free. For prices across labs, see the PSA test cost guide.

Is there a better screening test than PSA yet?

Not yet. A 2026 European study found circulating proteins associated with prostate cancer risk more than 10 years before diagnosis, but it is early research, not a screening test. Huang and colleagues measured more than 6,000 plasma proteins in 982 men who later developed prostate cancer and 1,573 comparison participants in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. ^[6]

Several proteins were linked to overall or aggressive prostate cancer risk. The strongest was KLK3, the gene that encodes PSA itself. The authors report incomplete external replication in a U.S. cohort as a limitation, and conclude that the findings identify candidate risk factors that need further validation. ^[6] For now, PSA remains the first screening test in the AUA/SUO guideline. ^[1]

References

1. American Urological Association. Early Detection of Prostate Cancer: AUA/SUO Guideline (2023; amended 2026).
2. US Preventive Services Task Force. Prostate Cancer: Screening. Final Recommendation Statement. May 8, 2018.
3. Monda SM, Odayar V, Yin M, et al. Population-level diagnostic and radiation treatment trends of low-risk prostate cancer. Cancer. 2026;132(21):e70603. doi:10.1002/cncr.70603
4. American Urological Association. Clinically Localized Prostate Cancer: AUA/ASTRO Guideline (2022; amended 2026).
5. National Cancer Institute. Prostate-Specific Antigen (PSA) Test.
6. Huang Z, Parsaeian M, Viallon V, et al. Circulating immune and cancer driver gene biomarkers precede prostate cancer diagnosis by over 10 yr. Eur Urol. 2026. doi:10.1016/j.eururo.2026.08.014